Connect With Us on Twitter
For Op-Ed, follow @nytopinion and to hear from the editorial page editor, Andrew Rosenthal, follow @andyrNYT.
"Battle in States on Generic Copies of Biotech Drugs" (front page, Jan. 29) addressed the complexities of cutting-edge biotech drugs and the important differences between them and conventional medicines.
As the article points out, even slight changes to a biologic drug can change its properties entirely. Unlike conventional generic medicines, biosimilars are not the same as the drugs they seek to substitute. In fact, two biologics made using different cell lines and differing manufacturing processes will rarely, if ever, be exactly the same, hence the name "biosimilar." Therefore, the decision to change to a biosimilar treatment is best made by doctor and patient.
As states continue to address issues related to biosimilars, we encourage all policy makers to continue to put patient safety first. We must ensure that the physician-patient relationship is maintained and that the patient and physician are notified of any potential substitution.
JIM GREENWOOD
President and Chief Executive
Biotechnology Industry Organization
Washington, Jan. 29, 2013
Anda sedang membaca artikel tentang
Letter: Generics and Patient Safety
Dengan url
http://opinimasyarakota.blogspot.com/2013/02/letter-generics-and-patient-safety.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Letter: Generics and Patient Safety
namun jangan lupa untuk meletakkan link
Letter: Generics and Patient Safety
sebagai sumbernya
0 komentar:
Posting Komentar